LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that it has signed a multi-year collaboration agreement with Hoffmann La Roche, Inc. (“Roche”) that will provide funding for the equivalent of one full-time scientist for two years to expand the capabilities of its flagship GastroPlus™ software program. The agreement includes close collaboration with Roche scientists to advance the capabilities of GastroPlus in the area of simulating drug-drug interactions.
